
Global Central Nervous System (CNS) Drug Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Central Nervous System (CNS) Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Central Nervous System (CNS) Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.
The Asia-Pacific market for Central Nervous System (CNS) Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Central Nervous System (CNS) Drug market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.
The Europe market for Central Nervous System (CNS) Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Central Nervous System (CNS) Drug market include Tekeda, Teva, Shanghai Fosun, Johnson & Johnson, Novartis AG, Roche, Eli Lilly, Jiangsu Nhwa Pharmaceutical Co., Ltd. and Pfizer Inc, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.
This report presents an overview of global market for Central Nervous System (CNS) Drug, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Central Nervous System (CNS) Drug, also provides the value of main regions and countries. Of the upcoming market potential for Central Nervous System (CNS) Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Central Nervous System (CNS) Drug revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Central Nervous System (CNS) Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Central Nervous System (CNS) Drug company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Central Nervous System (CNS) Drug Segment by Company
Tekeda
Teva
Shanghai Fosun
Johnson & Johnson
Novartis AG
Roche
Eli Lilly
Jiangsu Nhwa Pharmaceutical Co., Ltd.
Pfizer Inc
GSK
UCB
Otsuka Pharmaceutical Co., Ltd
Boehringer Ingelheim
Biogen Inc
Central Nervous System (CNS) Drug Segment by Type
Prescription Drugs
OTC
Central Nervous System (CNS) Drug Segment by Application
Epilepsy Drugs
MS Therapeutics
Antipsychotic Drugs
Depression Drugs
Others
Central Nervous System (CNS) Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Central Nervous System (CNS) Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Central Nervous System (CNS) Drug key companies, revenue, market share, and recent developments.
3. To split the Central Nervous System (CNS) Drug breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Central Nervous System (CNS) Drug market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Central Nervous System (CNS) Drug significant trends, drivers, influence factors in global and regions.
6. To analyze Central Nervous System (CNS) Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Central Nervous System (CNS) Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Central Nervous System (CNS) Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Central Nervous System (CNS) Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Central Nervous System (CNS) Drug industry.
Chapter 3: Detailed analysis of Central Nervous System (CNS) Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Central Nervous System (CNS) Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Central Nervous System (CNS) Drug in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
According to APO Research, the global Central Nervous System (CNS) Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Central Nervous System (CNS) Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.
The Asia-Pacific market for Central Nervous System (CNS) Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Central Nervous System (CNS) Drug market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.
The Europe market for Central Nervous System (CNS) Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Central Nervous System (CNS) Drug market include Tekeda, Teva, Shanghai Fosun, Johnson & Johnson, Novartis AG, Roche, Eli Lilly, Jiangsu Nhwa Pharmaceutical Co., Ltd. and Pfizer Inc, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.
This report presents an overview of global market for Central Nervous System (CNS) Drug, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Central Nervous System (CNS) Drug, also provides the value of main regions and countries. Of the upcoming market potential for Central Nervous System (CNS) Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Central Nervous System (CNS) Drug revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Central Nervous System (CNS) Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Central Nervous System (CNS) Drug company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Central Nervous System (CNS) Drug Segment by Company
Tekeda
Teva
Shanghai Fosun
Johnson & Johnson
Novartis AG
Roche
Eli Lilly
Jiangsu Nhwa Pharmaceutical Co., Ltd.
Pfizer Inc
GSK
UCB
Otsuka Pharmaceutical Co., Ltd
Boehringer Ingelheim
Biogen Inc
Central Nervous System (CNS) Drug Segment by Type
Prescription Drugs
OTC
Central Nervous System (CNS) Drug Segment by Application
Epilepsy Drugs
MS Therapeutics
Antipsychotic Drugs
Depression Drugs
Others
Central Nervous System (CNS) Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Central Nervous System (CNS) Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Central Nervous System (CNS) Drug key companies, revenue, market share, and recent developments.
3. To split the Central Nervous System (CNS) Drug breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Central Nervous System (CNS) Drug market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Central Nervous System (CNS) Drug significant trends, drivers, influence factors in global and regions.
6. To analyze Central Nervous System (CNS) Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Central Nervous System (CNS) Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Central Nervous System (CNS) Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Central Nervous System (CNS) Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Central Nervous System (CNS) Drug industry.
Chapter 3: Detailed analysis of Central Nervous System (CNS) Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Central Nervous System (CNS) Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Central Nervous System (CNS) Drug in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
Table of Contents
192 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Central Nervous System (CNS) Drug Market Size, 2020 VS 2024 VS 2031
- 1.3 Global Central Nervous System (CNS) Drug Market Size (2020-2031)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
- 2 Central Nervous System (CNS) Drug Market Dynamics
- 2.1 Central Nervous System (CNS) Drug Industry Trends
- 2.2 Central Nervous System (CNS) Drug Industry Drivers
- 2.3 Central Nervous System (CNS) Drug Industry Opportunities and Challenges
- 2.4 Central Nervous System (CNS) Drug Industry Restraints
- 3 Central Nervous System (CNS) Drug Market by Company
- 3.1 Global Central Nervous System (CNS) Drug Company Revenue Ranking in 2024
- 3.2 Global Central Nervous System (CNS) Drug Revenue by Company (2020-2025)
- 3.3 Global Central Nervous System (CNS) Drug Company Ranking (2023-2025)
- 3.4 Global Central Nervous System (CNS) Drug Company Manufacturing Base and Headquarters
- 3.5 Global Central Nervous System (CNS) Drug Company Product Type and Application
- 3.6 Global Central Nervous System (CNS) Drug Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Central Nervous System (CNS) Drug Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.7.3 2024 Central Nervous System (CNS) Drug Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
- 4 Central Nervous System (CNS) Drug Market by Type
- 4.1 Central Nervous System (CNS) Drug Type Introduction
- 4.1.1 Prescription Drugs
- 4.1.2 OTC
- 4.2 Global Central Nervous System (CNS) Drug Sales Value by Type
- 4.2.1 Global Central Nervous System (CNS) Drug Sales Value by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Central Nervous System (CNS) Drug Sales Value by Type (2020-2031)
- 4.2.3 Global Central Nervous System (CNS) Drug Sales Value Share by Type (2020-2031)
- 5 Central Nervous System (CNS) Drug Market by Application
- 5.1 Central Nervous System (CNS) Drug Application Introduction
- 5.1.1 Epilepsy Drugs
- 5.1.2 MS Therapeutics
- 5.1.3 Antipsychotic Drugs
- 5.1.4 Depression Drugs
- 5.1.5 Others
- 5.2 Global Central Nervous System (CNS) Drug Sales Value by Application
- 5.2.1 Global Central Nervous System (CNS) Drug Sales Value by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Central Nervous System (CNS) Drug Sales Value by Application (2020-2031)
- 5.2.3 Global Central Nervous System (CNS) Drug Sales Value Share by Application (2020-2031)
- 6 Central Nervous System (CNS) Drug Regional Value Analysis
- 6.1 Global Central Nervous System (CNS) Drug Sales Value by Region: 2020 VS 2024 VS 2031
- 6.2 Global Central Nervous System (CNS) Drug Sales Value by Region (2020-2031)
- 6.2.1 Global Central Nervous System (CNS) Drug Sales Value by Region: 2020-2025
- 6.2.2 Global Central Nervous System (CNS) Drug Sales Value by Region (2026-2031)
- 6.3 North America
- 6.3.1 North America Central Nervous System (CNS) Drug Sales Value (2020-2031)
- 6.3.2 North America Central Nervous System (CNS) Drug Sales Value Share by Country, 2024 VS 2031
- 6.4 Europe
- 6.4.1 Europe Central Nervous System (CNS) Drug Sales Value (2020-2031)
- 6.4.2 Europe Central Nervous System (CNS) Drug Sales Value Share by Country, 2024 VS 2031
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Central Nervous System (CNS) Drug Sales Value (2020-2031)
- 6.5.2 Asia-Pacific Central Nervous System (CNS) Drug Sales Value Share by Country, 2024 VS 2031
- 6.6 South America
- 6.6.1 South America Central Nervous System (CNS) Drug Sales Value (2020-2031)
- 6.6.2 South America Central Nervous System (CNS) Drug Sales Value Share by Country, 2024 VS 2031
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Central Nervous System (CNS) Drug Sales Value (2020-2031)
- 6.7.2 Middle East & Africa Central Nervous System (CNS) Drug Sales Value Share by Country, 2024 VS 2031
- 7 Central Nervous System (CNS) Drug Country-level Value Analysis
- 7.1 Global Central Nervous System (CNS) Drug Sales Value by Country: 2020 VS 2024 VS 2031
- 7.2 Global Central Nervous System (CNS) Drug Sales Value by Country (2020-2031)
- 7.2.1 Global Central Nervous System (CNS) Drug Sales Value by Country (2020-2025)
- 7.2.2 Global Central Nervous System (CNS) Drug Sales Value by Country (2026-2031)
- 7.3 USA
- 7.3.1 USA Central Nervous System (CNS) Drug Sales Value Growth Rate (2020-2031)
- 7.3.2 USA Central Nervous System (CNS) Drug Sales Value Share by Type, 2024 VS 2031
- 7.3.3 USA Central Nervous System (CNS) Drug Sales Value Share by Application, 2024 VS 2031
- 7.4 Canada
- 7.4.1 Canada Central Nervous System (CNS) Drug Sales Value Growth Rate (2020-2031)
- 7.4.2 Canada Central Nervous System (CNS) Drug Sales Value Share by Type, 2024 VS 2031
- 7.4.3 Canada Central Nervous System (CNS) Drug Sales Value Share by Application, 2024 VS 2031
- 7.5 Mexico
- 7.5.1 Mexico Central Nervous System (CNS) Drug Sales Value Growth Rate (2020-2031)
- 7.5.2 Mexico Central Nervous System (CNS) Drug Sales Value Share by Type, 2024 VS 2031
- 7.5.3 Mexico Central Nervous System (CNS) Drug Sales Value Share by Application, 2024 VS 2031
- 7.6 Germany
- 7.6.1 Germany Central Nervous System (CNS) Drug Sales Value Growth Rate (2020-2031)
- 7.6.2 Germany Central Nervous System (CNS) Drug Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Germany Central Nervous System (CNS) Drug Sales Value Share by Application, 2024 VS 2031
- 7.7 France
- 7.7.1 France Central Nervous System (CNS) Drug Sales Value Growth Rate (2020-2031)
- 7.7.2 France Central Nervous System (CNS) Drug Sales Value Share by Type, 2024 VS 2031
- 7.7.3 France Central Nervous System (CNS) Drug Sales Value Share by Application, 2024 VS 2031
- 7.8 U.K.
- 7.8.1 U.K. Central Nervous System (CNS) Drug Sales Value Growth Rate (2020-2031)
- 7.8.2 U.K. Central Nervous System (CNS) Drug Sales Value Share by Type, 2024 VS 2031
- 7.8.3 U.K. Central Nervous System (CNS) Drug Sales Value Share by Application, 2024 VS 2031
- 7.9 Italy
- 7.9.1 Italy Central Nervous System (CNS) Drug Sales Value Growth Rate (2020-2031)
- 7.9.2 Italy Central Nervous System (CNS) Drug Sales Value Share by Type, 2024 VS 2031
- 7.9.3 Italy Central Nervous System (CNS) Drug Sales Value Share by Application, 2024 VS 2031
- 7.10 Spain
- 7.10.1 Spain Central Nervous System (CNS) Drug Sales Value Growth Rate (2020-2031)
- 7.10.2 Spain Central Nervous System (CNS) Drug Sales Value Share by Type, 2024 VS 2031
- 7.10.3 Spain Central Nervous System (CNS) Drug Sales Value Share by Application, 2024 VS 2031
- 7.11 Russia
- 7.11.1 Russia Central Nervous System (CNS) Drug Sales Value Growth Rate (2020-2031)
- 7.11.2 Russia Central Nervous System (CNS) Drug Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Russia Central Nervous System (CNS) Drug Sales Value Share by Application, 2024 VS 2031
- 7.12 Netherlands
- 7.12.1 Netherlands Central Nervous System (CNS) Drug Sales Value Growth Rate (2020-2031)
- 7.12.2 Netherlands Central Nervous System (CNS) Drug Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Netherlands Central Nervous System (CNS) Drug Sales Value Share by Application, 2024 VS 2031
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Central Nervous System (CNS) Drug Sales Value Growth Rate (2020-2031)
- 7.13.2 Nordic Countries Central Nervous System (CNS) Drug Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Nordic Countries Central Nervous System (CNS) Drug Sales Value Share by Application, 2024 VS 2031
- 7.14 China
- 7.14.1 China Central Nervous System (CNS) Drug Sales Value Growth Rate (2020-2031)
- 7.14.2 China Central Nervous System (CNS) Drug Sales Value Share by Type, 2024 VS 2031
- 7.14.3 China Central Nervous System (CNS) Drug Sales Value Share by Application, 2024 VS 2031
- 7.15 Japan
- 7.15.1 Japan Central Nervous System (CNS) Drug Sales Value Growth Rate (2020-2031)
- 7.15.2 Japan Central Nervous System (CNS) Drug Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Japan Central Nervous System (CNS) Drug Sales Value Share by Application, 2024 VS 2031
- 7.16 South Korea
- 7.16.1 South Korea Central Nervous System (CNS) Drug Sales Value Growth Rate (2020-2031)
- 7.16.2 South Korea Central Nervous System (CNS) Drug Sales Value Share by Type, 2024 VS 2031
- 7.16.3 South Korea Central Nervous System (CNS) Drug Sales Value Share by Application, 2024 VS 2031
- 7.17 India
- 7.17.1 India Central Nervous System (CNS) Drug Sales Value Growth Rate (2020-2031)
- 7.17.2 India Central Nervous System (CNS) Drug Sales Value Share by Type, 2024 VS 2031
- 7.17.3 India Central Nervous System (CNS) Drug Sales Value Share by Application, 2024 VS 2031
- 7.18 Australia
- 7.18.1 Australia Central Nervous System (CNS) Drug Sales Value Growth Rate (2020-2031)
- 7.18.2 Australia Central Nervous System (CNS) Drug Sales Value Share by Type, 2024 VS 2031
- 7.18.3 Australia Central Nervous System (CNS) Drug Sales Value Share by Application, 2024 VS 2031
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Central Nervous System (CNS) Drug Sales Value Growth Rate (2020-2031)
- 7.19.2 Southeast Asia Central Nervous System (CNS) Drug Sales Value Share by Type, 2024 VS 2031
- 7.19.3 Southeast Asia Central Nervous System (CNS) Drug Sales Value Share by Application, 2024 VS 2031
- 7.20 Brazil
- 7.20.1 Brazil Central Nervous System (CNS) Drug Sales Value Growth Rate (2020-2031)
- 7.20.2 Brazil Central Nervous System (CNS) Drug Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Brazil Central Nervous System (CNS) Drug Sales Value Share by Application, 2024 VS 2031
- 7.21 Argentina
- 7.21.1 Argentina Central Nervous System (CNS) Drug Sales Value Growth Rate (2020-2031)
- 7.21.2 Argentina Central Nervous System (CNS) Drug Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Argentina Central Nervous System (CNS) Drug Sales Value Share by Application, 2024 VS 2031
- 7.22 Chile
- 7.22.1 Chile Central Nervous System (CNS) Drug Sales Value Growth Rate (2020-2031)
- 7.22.2 Chile Central Nervous System (CNS) Drug Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Chile Central Nervous System (CNS) Drug Sales Value Share by Application, 2024 VS 2031
- 7.23 Colombia
- 7.23.1 Colombia Central Nervous System (CNS) Drug Sales Value Growth Rate (2020-2031)
- 7.23.2 Colombia Central Nervous System (CNS) Drug Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Colombia Central Nervous System (CNS) Drug Sales Value Share by Application, 2024 VS 2031
- 7.24 Peru
- 7.24.1 Peru Central Nervous System (CNS) Drug Sales Value Growth Rate (2020-2031)
- 7.24.2 Peru Central Nervous System (CNS) Drug Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Peru Central Nervous System (CNS) Drug Sales Value Share by Application, 2024 VS 2031
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Central Nervous System (CNS) Drug Sales Value Growth Rate (2020-2031)
- 7.25.2 Saudi Arabia Central Nervous System (CNS) Drug Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Saudi Arabia Central Nervous System (CNS) Drug Sales Value Share by Application, 2024 VS 2031
- 7.26 Israel
- 7.26.1 Israel Central Nervous System (CNS) Drug Sales Value Growth Rate (2020-2031)
- 7.26.2 Israel Central Nervous System (CNS) Drug Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Israel Central Nervous System (CNS) Drug Sales Value Share by Application, 2024 VS 2031
- 7.27 UAE
- 7.27.1 UAE Central Nervous System (CNS) Drug Sales Value Growth Rate (2020-2031)
- 7.27.2 UAE Central Nervous System (CNS) Drug Sales Value Share by Type, 2024 VS 2031
- 7.27.3 UAE Central Nervous System (CNS) Drug Sales Value Share by Application, 2024 VS 2031
- 7.28 Turkey
- 7.28.1 Turkey Central Nervous System (CNS) Drug Sales Value Growth Rate (2020-2031)
- 7.28.2 Turkey Central Nervous System (CNS) Drug Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Turkey Central Nervous System (CNS) Drug Sales Value Share by Application, 2024 VS 2031
- 7.29 Iran
- 7.29.1 Iran Central Nervous System (CNS) Drug Sales Value Growth Rate (2020-2031)
- 7.29.2 Iran Central Nervous System (CNS) Drug Sales Value Share by Type, 2024 VS 2031
- 7.29.3 Iran Central Nervous System (CNS) Drug Sales Value Share by Application, 2024 VS 2031
- 7.30 Egypt
- 7.30.1 Egypt Central Nervous System (CNS) Drug Sales Value Growth Rate (2020-2031)
- 7.30.2 Egypt Central Nervous System (CNS) Drug Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Egypt Central Nervous System (CNS) Drug Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Tekeda
- 8.1.1 Tekeda Comapny Information
- 8.1.2 Tekeda Business Overview
- 8.1.3 Tekeda Central Nervous System (CNS) Drug Revenue and Gross Margin (2020-2025)
- 8.1.4 Tekeda Central Nervous System (CNS) Drug Product Portfolio
- 8.1.5 Tekeda Recent Developments
- 8.2 Teva
- 8.2.1 Teva Comapny Information
- 8.2.2 Teva Business Overview
- 8.2.3 Teva Central Nervous System (CNS) Drug Revenue and Gross Margin (2020-2025)
- 8.2.4 Teva Central Nervous System (CNS) Drug Product Portfolio
- 8.2.5 Teva Recent Developments
- 8.3 Shanghai Fosun
- 8.3.1 Shanghai Fosun Comapny Information
- 8.3.2 Shanghai Fosun Business Overview
- 8.3.3 Shanghai Fosun Central Nervous System (CNS) Drug Revenue and Gross Margin (2020-2025)
- 8.3.4 Shanghai Fosun Central Nervous System (CNS) Drug Product Portfolio
- 8.3.5 Shanghai Fosun Recent Developments
- 8.4 Johnson & Johnson
- 8.4.1 Johnson & Johnson Comapny Information
- 8.4.2 Johnson & Johnson Business Overview
- 8.4.3 Johnson & Johnson Central Nervous System (CNS) Drug Revenue and Gross Margin (2020-2025)
- 8.4.4 Johnson & Johnson Central Nervous System (CNS) Drug Product Portfolio
- 8.4.5 Johnson & Johnson Recent Developments
- 8.5 Novartis AG
- 8.5.1 Novartis AG Comapny Information
- 8.5.2 Novartis AG Business Overview
- 8.5.3 Novartis AG Central Nervous System (CNS) Drug Revenue and Gross Margin (2020-2025)
- 8.5.4 Novartis AG Central Nervous System (CNS) Drug Product Portfolio
- 8.5.5 Novartis AG Recent Developments
- 8.6 Roche
- 8.6.1 Roche Comapny Information
- 8.6.2 Roche Business Overview
- 8.6.3 Roche Central Nervous System (CNS) Drug Revenue and Gross Margin (2020-2025)
- 8.6.4 Roche Central Nervous System (CNS) Drug Product Portfolio
- 8.6.5 Roche Recent Developments
- 8.7 Eli Lilly
- 8.7.1 Eli Lilly Comapny Information
- 8.7.2 Eli Lilly Business Overview
- 8.7.3 Eli Lilly Central Nervous System (CNS) Drug Revenue and Gross Margin (2020-2025)
- 8.7.4 Eli Lilly Central Nervous System (CNS) Drug Product Portfolio
- 8.7.5 Eli Lilly Recent Developments
- 8.8 Jiangsu Nhwa Pharmaceutical Co., Ltd.
- 8.8.1 Jiangsu Nhwa Pharmaceutical Co., Ltd. Comapny Information
- 8.8.2 Jiangsu Nhwa Pharmaceutical Co., Ltd. Business Overview
- 8.8.3 Jiangsu Nhwa Pharmaceutical Co., Ltd. Central Nervous System (CNS) Drug Revenue and Gross Margin (2020-2025)
- 8.8.4 Jiangsu Nhwa Pharmaceutical Co., Ltd. Central Nervous System (CNS) Drug Product Portfolio
- 8.8.5 Jiangsu Nhwa Pharmaceutical Co., Ltd. Recent Developments
- 8.9 Pfizer Inc
- 8.9.1 Pfizer Inc Comapny Information
- 8.9.2 Pfizer Inc Business Overview
- 8.9.3 Pfizer Inc Central Nervous System (CNS) Drug Revenue and Gross Margin (2020-2025)
- 8.9.4 Pfizer Inc Central Nervous System (CNS) Drug Product Portfolio
- 8.9.5 Pfizer Inc Recent Developments
- 8.10 GSK
- 8.10.1 GSK Comapny Information
- 8.10.2 GSK Business Overview
- 8.10.3 GSK Central Nervous System (CNS) Drug Revenue and Gross Margin (2020-2025)
- 8.10.4 GSK Central Nervous System (CNS) Drug Product Portfolio
- 8.10.5 GSK Recent Developments
- 8.11 UCB
- 8.11.1 UCB Comapny Information
- 8.11.2 UCB Business Overview
- 8.11.3 UCB Central Nervous System (CNS) Drug Revenue and Gross Margin (2020-2025)
- 8.11.4 UCB Central Nervous System (CNS) Drug Product Portfolio
- 8.11.5 UCB Recent Developments
- 8.12 Otsuka Pharmaceutical Co., Ltd
- 8.12.1 Otsuka Pharmaceutical Co., Ltd Comapny Information
- 8.12.2 Otsuka Pharmaceutical Co., Ltd Business Overview
- 8.12.3 Otsuka Pharmaceutical Co., Ltd Central Nervous System (CNS) Drug Revenue and Gross Margin (2020-2025)
- 8.12.4 Otsuka Pharmaceutical Co., Ltd Central Nervous System (CNS) Drug Product Portfolio
- 8.12.5 Otsuka Pharmaceutical Co., Ltd Recent Developments
- 8.13 Boehringer Ingelheim
- 8.13.1 Boehringer Ingelheim Comapny Information
- 8.13.2 Boehringer Ingelheim Business Overview
- 8.13.3 Boehringer Ingelheim Central Nervous System (CNS) Drug Revenue and Gross Margin (2020-2025)
- 8.13.4 Boehringer Ingelheim Central Nervous System (CNS) Drug Product Portfolio
- 8.13.5 Boehringer Ingelheim Recent Developments
- 8.14 Biogen Inc
- 8.14.1 Biogen Inc Comapny Information
- 8.14.2 Biogen Inc Business Overview
- 8.14.3 Biogen Inc Central Nervous System (CNS) Drug Revenue and Gross Margin (2020-2025)
- 8.14.4 Biogen Inc Central Nervous System (CNS) Drug Product Portfolio
- 8.14.5 Biogen Inc Recent Developments
- 9 Concluding Insights
- 10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.